Astellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough Therapies
Astellas Pharma Inc. (TSE: 4503) has unveiled its new Astellas Life Sciences Center (ALSC) in Cambridge, Massachusetts. This LEED-certified facility aims to accelerate the discovery of breakthrough therapies through collaboration and innovation. Key features include:
1. The first U.S.-based SakuLab™, an open innovation incubator space for external partners.
2. Home to the Engineered Small Molecules (ESM) unit, focusing on targeted protein degradation research.
3. Workspace for approximately 400 Astellas employees from various departments.
4. Designed to foster collaboration with local academic institutions and biotech innovators.
The ALSC joins Astellas' growing presence in Massachusetts, complementing the Astellas Institute of Regenerative Medicine (AIRM) in Westborough, launched in 2020.
Astellas Pharma Inc. (TSE: 4503) ha svelato il suo nuovo Astellas Life Sciences Center (ALSC) a Cambridge, Massachusetts. Questa struttura certificata LEED mira ad accelerare la scoperta di terapie rivoluzionarie attraverso la collaborazione e l'innovazione. Le caratteristiche principali includono:
1. Il primo SakuLab™ negli Stati Uniti, uno spazio incubatore di innovazione aperto per partner esterni.
2. Sede dell'unità Engineered Small Molecules (ESM), focalizzata sulla ricerca nel degrado mirato delle proteine.
3. Spazio di lavoro per circa 400 dipendenti Astellas provenienti da vari reparti.
4. Progettato per favorire la collaborazione con istituzioni accademiche locali e innovatori biotech.
Il ALSC si aggiunge alla crescente presenza di Astellas in Massachusetts, completando l'Astellas Institute of Regenerative Medicine (AIRM) a Westborough, inaugurato nel 2020.
Astellas Pharma Inc. (TSE: 4503) ha presentado su nuevo Astellas Life Sciences Center (ALSC) en Cambridge, Massachusetts. Esta instalación certificada por LEED tiene como objetivo acelerar el descubrimiento de terapias innovadoras a través de la colaboración y la innovación. Las características clave incluyen:
1. El primer SakuLab™ con sede en EE. UU., un espacio de incubadora de innovación abierta para socios externos.
2. Hogar de la unidad de Engineered Small Molecules (ESM), centrada en la investigación sobre la degradación selectiva de proteínas.
3. Espacio de trabajo para aproximadamente 400 empleados de Astellas de varios departamentos.
4. Diseñado para fomentar la colaboración con instituciones académicas locales e innovadores de biotecnología.
El ALSC se une a la creciente presencia de Astellas en Massachusetts, complementando el Astellas Institute of Regenerative Medicine (AIRM) en Westborough, lanzado en 2020.
Astellas Pharma Inc. (TSE: 4503)은 매사추세츠주 캠브리지에 새로운 Astellas Life Sciences Center (ALSC)를 공개했습니다. 이 LEED 인증 시설은 협업과 혁신을 통해 혁신적인 치료법 발견을 가속화하는 것을 목표로 합니다. 주요 특징은 다음과 같습니다:
1. 외부 파트너를 위한 개방형 혁신 인큐베이터 공간인 미국 최초의 SakuLab™.
2. 표적 단백질 분해 연구에 중점을 둔 Engineered Small Molecules (ESM) 부서의 본부.
3. 다양한 부서에서 약 400명의 Astellas 직원이 근무하는 작업 공간.
4. 지역 학술 기관 및 바이오텍 혁신자와의 협업을 촉진하도록 설계되었습니다.
ALSC는 2020년에 설립된 웨스트버러에 있는 Astellas Institute of Regenerative Medicine (AIRM)을 보완하며 매사추세츠 내 Astellas의 성장하는 존재감에 기여합니다.
Astellas Pharma Inc. (TSE: 4503) a dévoilé son nouveau Astellas Life Sciences Center (ALSC) à Cambridge, Massachusetts. Cette installation certifiée LEED vise à accélérer la découverte de thérapies révolutionnaires grâce à la collaboration et à l'innovation. Les caractéristiques clés comprennent :
1. Le premier SakuLab™ basé aux États-Unis, un espace d'incubation d'innovation ouvert pour des partenaires externes.
2. Siège de l'unité Engineered Small Molecules (ESM), axée sur la recherche sur la dégradation ciblée des protéines.
3. Espace de travail pour environ 400 employés d'Astellas provenant de divers départements.
4. Conçu pour favoriser la collaboration avec des institutions académiques locales et des innovateurs en biotechnologie.
Le ALSC s'ajoute à la présence croissante d'Astellas dans le Massachusetts, complétant l'Astellas Institute of Regenerative Medicine (AIRM) à Westborough, lancé en 2020.
Astellas Pharma Inc. (TSE: 4503) hat sein neues Astellas Life Sciences Center (ALSC) in Cambridge, Massachusetts, eröffnet. Diese LEED-zertifizierte Einrichtung zielt darauf ab, die Entdeckung bahnbrechender Therapien durch Zusammenarbeit und Innovation zu beschleunigen. Zu den Hauptmerkmalen gehören:
1. Das erste in den USA ansässige SakuLab™, ein Raum für offene Innovationsinkubation für externe Partner.
2. Sitz der Engineered Small Molecules (ESM) Einheit, die sich auf Forschung zur gezielten Proteinabbau konzentriert.
3. Arbeitsbereich für etwa 400 Astellas-Mitarbeiter aus verschiedenen Abteilungen.
4. Gestaltet, um die Zusammenarbeit mit lokalen akademischen Institutionen und Biotech-Innovatoren zu fördern.
Das ALSC ergänzt die wachsende Präsenz von Astellas in Massachusetts und ergänzt das Astellas Institute of Regenerative Medicine (AIRM) in Westborough, das 2020 gegründet wurde.
- Establishment of a new Life Sciences Center in Cambridge, MA, a key biotech hub
- Introduction of the first U.S.-based SakuLab™ for open innovation and collaboration
- Focus on advanced research in targeted protein degradation
- Potential for accelerated discovery and development of breakthrough therapies
- Expansion of Astellas' presence and impact in Massachusetts
- None.
The Astellas Life Sciences Center hosts the company's first
The new LEED-certified construction is home to the company's first
Approximately 400 Astellas employees will operate out of the new building, representing Medical & Development, Business Development and Research. By providing shared R&D resources, flexible workspaces, and dedicated areas for cross-functional and partner collaboration, the new facility enables Astellas teams to work together more cohesively and capitalize on the diverse expertise within the company and outside our walls to trailblaze the next generation of healthcare solutions.
Tadaaki Taniguchi, M.D., Ph.D., Chief Medical Officer, Astellas
"Our new Astellas Life Sciences Center and open innovation SakuLab will advance our efforts to deliver breakthrough therapies and novel modalities, with a focus on areas of high unmet need. It will also strengthen our partnerships with local academic institutions and biotech innovators, underpinning our commitment to pursue transformative treatments in oncology, ophthalmology and rare diseases for patients in need."
Fostering External Research Collaborations to Nurture Innovation and Drug Discovery
The SakuLab at
Inspired by the Japanese word "saku," which in English translates to "to bloom," Astellas SakuLabs are designed to nurture and grow ideas. These open innovation hubs strive to create unique shared workspaces where bold and diverse ideas can flourish, in hopes of advancing groundbreaking discoveries that will make a meaningful difference for patients.
Expanding Astellas' Impact in
The new
About Astellas
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at https://www.astellas.com/en.
Cautionary Notes (Astellas)
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
View original content to download multimedia:https://www.prnewswire.com/news-releases/astellas-unveils-new-life-sciences-center-in-cambridge-massachusetts-to-accelerate-the-discovery-of-breakthrough-therapies-302239370.html
SOURCE ASTELLAS PHARMA INC.
FAQ
What is the purpose of Astellas' new Life Sciences Center in Cambridge, MA?
What is SakuLab™ and how does it relate to Astellas (ALPMY)?
What research focus does the Engineered Small Molecules (ESM) unit have at the new Astellas facility?
How many employees will work at the new Astellas Life Sciences Center in Cambridge?
